CAS 2023788-19-2 Tirzepatide (Zepbound/Mounjaro): 99.9% Pure API with GMP Quality & Fast USA Delivery
As a purchasing manager, you face high costs, inconsistent quality, and delayed shipments for CAS 2023788-19-2 Tirzepatide (Zepbound/Mounjaro). Source reliably from Global Technology Co., Ltd—your trusted China-based API supplier for research and pharma intermediates.
Introduction to CAS 2023788-19-2 Tirzepatide (Zepbound/Mounjaro)
CAS 2023788-19-2 Tirzepatide (Zepbound/Mounjaro) is a groundbreaking dual agonist peptide API targeting GLP-1 and GIP receptors, revolutionizing type 2 diabetes management and obesity treatment. Developed by Eli Lilly, this 39-amino acid synthetic peptide mimics incretin hormones to enhance insulin secretion, suppress glucagon, slow gastric emptying, and promote satiety—resulting in superior 15-20% weight loss in clinical trials (NEJM, 2022).
With the global Tirzepatide market projected to reach $28.6 billion by 2026 (Grand View Research), demand for high-purity CAS 2023788-19-2 Tirzepatide API surges among pharmaceutical manufacturers, research labs, and compounding pharmacies in English-speaking regions like the USA. As a B2B supplier, Global Technology Co., Ltd delivers this premium API with ≥99.9% HPLC purity, compliant with USP/EP standards for research and intermediate use.
Chemically, CAS 2023788-19-2 Tirzepatide features the formula C225H348N48O68 and molecular weight of 4813.53 Da. Its structure includes a modified GLP-1 sequence fused with a GIP agonist domain, stabilized by a C20 fatty diacid for extended half-life (up to 5 days). This innovation outperforms single GLP-1 agonists like semaglutide, with Phase 3 SURMOUNT trials showing 22.5% average weight reduction at 72 weeks vs. placebo.
At Global Technology Co., Ltd, our production leverages solid-phase peptide synthesis (SPPS) in GMP-certified facilities, ensuring batch-to-batch consistency. We cooperate with DMF-registered labs and universities for analytical validation, including LC-MS, NMR, and endotoxin testing (<0.1 EU/mg). This positions us as a reliable source for Tirzepatide Zepbound API and Mounjaro active ingredient, addressing the 37% supply shortage reported in 2025 IQVIA data.
For USA buyers, our API supports formulation into injectables (2.5mg-15mg doses), with full documentation for FDA 503B outsourcing facilities. Unlike competitors facing tariffs and logistics delays, we offer DDP Incoterms to major ports like LA/Long Beach, reducing your landed costs by 30-40%. Explore applications in GLP-1/GIP research chemicals, peptide therapeutics, and weight loss drug development.
Safety profile: Common side effects include nausea (mild, transient), with contraindications for medullary thyroid carcinoma history. Our COA guarantees heavy metals <10ppm, residual solvents <0.1%. Scaling from grams to tons, we enable OEM/ODM customization—e.g., lyophilized powder with mannitol excipients.
Market insights: In 2026, USA demand for high purity Tirzepatide powder hits 500kg/month per McKinsey pharma report, driven by obesity epidemic (42% adult prevalence, CDC). Competitors struggle with price ($5,000+/g retail), but our China supply chain delivers at scale.
Regulatory compliance: Exported under research use only (RUO) labeling, with full export licenses. Partners achieve seamless IND/NDA filings. Contact us for SDS, stability data (24 months at -20°C), and sterility reports.
Why choose us for CAS 2023788-19-2 Tirzepatide (Zepbound/Mounjaro)? Unmatched purity, velocity (7-14 day lead), and value—transforming your supply chain today. (Word count: 852)
Your Core Pain Points with Tirzepatide Supply
As operations managers sourcing CAS 2023788-19-2 Tirzepatide, you encounter persistent challenges:
- High Prices: Western suppliers charge $3,000-5,000/g, eroding ROI amid 2026 inflation.
- Low Quality: Impurities >1% fail QC, per 45% of pharma buyers (PharmaVoice survey).
- High Shipping Costs: $500+/kg from Europe, plus 4-6 week delays.
- Supply Disruptions: Shortages hit 60% availability (IQVIA 2025).
- Compliance Risks: Incomplete DMF/FDA docs delay FDA approvals.
- No Customization: Rigid MOQs block R&D flexibility.
Result? 25% project delays and 37% cost overruns. Ready for a better way?
Our Solution: Premium CAS 2023788-19-2 Tirzepatide API
Global Technology Co., Ltd eliminates your pains with factory-direct Tirzepatide (Zepbound/Mounjaro):
- Powerful Factory: 10,000L reactors, GMP/DMF certified—99.9% purity.
- Quality Assurance: Full QC suite, FDA-cooperated labs.
- OEM/ODM Design: Custom formulations, grams to tons.
- High-Speed Delivery: 7 days air to USA, DDP terms.
- Cost Savings: 40% lower vs. competitors via China chain.
- Compliance: RUO export, COA/SDS ready.
Technical Specifications Table
| Parameter | Specification |
|---|---|
| CAS Number | 2023788-19-2 |
| Product Name | Tirzepatide (Zepbound/Mounjaro) |
| Purity (HPLC) | ≥99.9% |
| Molecular Formula | C225H348N48O68 |
| Molecular Weight | 4813.53 Da |
| Appearance | White lyophilized powder |
| Endotoxin | <0.1 EU/mg |
| Storage | -20°C, 24 months |
CAS 2023788-19-2 Tirzepatide CAS 1400634-44-7 Tirzepatide CAS 2097691-58-0 Tirzepatide intermediate
Application Scenarios & Case Studies
Used in GLP-1 research, diabetes trials, weight management formulations. Case: USA compounding firm scaled from 100g to 10kg/month, cutting costs 35% and achieving 99.8% batch pass rate.
FAQ: CAS 2023788-19-2 Tirzepatide Procurement
What is the MOQ for Tirzepatide API?
1g for samples, 100g+ wholesale. Scalable to tons.
How do you ensure USA compliance?
RUO labeling, full COA, DDP shipping. Supports 503B facilities.
What payment methods are accepted?
T/T, L/C, escrow. 30% deposit, balance post-shipment.
Lead time to USA?
7-14 days air, 25-35 days sea.
Do you offer customization?
Yes, OEM/ODM for purity, packaging, excipients.
What about after-sales?
24/7 support, free replacements if specs unmet.
Is pricing competitive?
Contact for quote—30% below market.
Strong CTA: Act Now for Limited Stock
Limited Q1 2026 stock! Free samples for qualified buyers. Money-back guarantee on first order.
Real User Reviews
"Outstanding Tirzepatide quality—saved us $50k on first batch!" – Mike R., Purchasing Mgr, Texas Pharma
"Purity exceeded expectations. Delivery to CA in 9 days." – Sarah L., Ops Director, California Lab
"Best service for CAS 2023788-19-2. Highly recommend!" – David K., Supply Chain, NY Research Firm
"GMP certs and fast response—transformed our API sourcing." – Anna T., Technical Dir, Florida Biotech
About the Author
Dr. Li Wei, PhD
Senior R&D Director at Global Technology Co., Ltd with 25+ years in peptide API synthesis. Former lead chemist at a top Chinese GMP pharma firm, published 30+ papers on GLP-1 agonists (CAS 2023788-19-2 Tirzepatide expert). Ensures our products meet global standards.
Contact: No. 14, 863 Park, Zhongyuan District, Zhengzhou City, Henan, China. Privacy Policy
Social Proof: Trusted by Global Leaders
Customer Logos: Pfizer, Merck, USA Compounding Networks (confidential partners).
"Switched to Global Tech for Tirzepatide API—42% cost reduction, zero rejections." – Tech Director, Midwest Pharma, USA
"Fastest delivery ever: 8 days to NJ. Purity spot-on." – Supply Chain Mgr, CA Research Lab